|
|
Post by mnholdem on Feb 4, 2016 14:59:53 GMT -5
This company does seem to fit the profile of some the indicators mentioned in the press release.
ABOUT OMEROS
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
PIPELINE
Omeros is developing a deep pipeline of small-molecule and protein therapeutic candidates targeting inflammation, coagulopathies, and disorders of the central nervous system. Our twelve programs include those focused on inflammation, coagulopathies, and multiple CNS disorders, as well as our three platform programs: PharmacoSurgery®, antibody and G protein-coupled receptor all targeting both large-market and exciting orphan opportunities.
Source: www.omeros.com/pipeline/pipeline.htm
NOTE: Omeros is a public-traded company, however [NASDAQ: OMER]. Unless they are planning a spinoff, there is no indication of an imminent name-change.
|
|
|
|
Post by cathode on Feb 4, 2016 15:16:58 GMT -5
My doubt about Omeros is that they are a public company, though as lakers mentioned, perhaps this is an R&D limb or something. (Good edit mnholdem) I currently think that Algomedix (who's president is the former director of discovery research at Omeros) might fit the bill a little better. Maybe Algomedix is already an R&D limb of Omeros -- I don't know. I have found very little about Algomedix. The Internet Archive's Wayback Machine doesn't help because their website has been basically static since 2013. |
|
|
|
Post by lakers on Feb 4, 2016 15:44:54 GMT -5
Click to see a nice table of GPCR drug candidates: www.omeros.com/pipeline/gpcr.htmGPCR Metabolic & Cardiovascular Indications GPCR Oncology Indications GPR12 Obesity, Cognitive Impairments GPR19 Melanoma, Lung CancerGPR21 Obesity, Diabetes GPR20 Gastro-Intestinal Stromal Tumors, Acute Myeloid Leukemia GPR22 Cardiovascular Diseases, Anxiety GPR65 Renal Cell Carcinoma, Ovarian Cancer, Inflammation GPR25 Arterial Stiffness GPR68 Ovarian Cancer, Prostate Cancer, OsteoporosisGPR37L1 Hypertension GPR80 Hepatocellular Carcinoma GPR39 Diabetes GPR87 Squamous Cell Carcinoma GPR50 Metabolic Disorders GPR150 Ovarian Cancer GPR61 Eating Disorders GPR161 Breast Cancer, Congenital Cataracts & Birth Defects GPR82 Appetite, Body Weight GPR174 Melanoma, Grave’s Disease GPR101 Eating Disorders LGR4 Cancer Stem Cells, Bone Diseases GPR132 Atherosclerosis LGR5 Cancer Stem Cells, Esophageal Adenocarcinoma GPR146 Dyslipidemia, Diabetes P2Y8 Leukemias, Lymphomas
GPR171 Eating Disorders GPR176 Atherosclerosis SREB1/GPR27 Diabetes, Schizophrenia GPCR CNS Indications GPCR Miscellaneous Indications GPR17 Myelin Disorders, Multiple Sclerosis GPR15 HIV Enteropathy, Rheumatoid ArthritisGPR31 Anxiety Disorders GPR32 Acute Inflammatory Responses
GPR37 Parkinson’s Disease GPR83 Autoimmune Diseases, PTSD GPR52 Schizophrenia GPR183 Humoral Immunity GPR63 Autism CCRL2 Rheumatoid ArthritisGPR78 Bipolar Disorder, Schizophrenia LGR6 Hair Follicle Stem Cells, Wound Repair GPR139 Motor Disorders GPCRs with Unknown Indications GPR151 Cognition, Mood Disorders, Pain GPR45 GPR182 GPR135 MRGF GPR141 OPN5 GPR162 GPR153 Schizophrenia MAS1 Cognitive Impairments MRGE PainOPN4 Circadian Rhythm, Sleep Disorders SREB2/GPR85 Schizophrenia, ObesitySREB3/GPR173 Schizophrenia, ObesityCommercial markets The GPCR family represents an important source of drug discovery. Of the 363 characterized GPCRs, only about 46 are currently targeted by marketed drugs, yet GPCR-targeted drugs account for 30-40% of all drugs sold worldwide. G protein-coupled receptors ( GPCRs), which mediate key physiological processes in the body, are one of the most valuable families of drug targets. According to Insight Pharma Reports, GPCR-targeting drugs represent 30 to 40 percent of marketed pharmaceuticals. Examples include Claritin® (allergy), Zantac® (ulcers and reflux), OxyContin® (pain), Lopressor® (high blood pressure), Imitrex® (migraine headache), Reglan® (nausea) and Abilify® (schizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics.
The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Without a known ligand, drug development for a given receptor is extremely difficult.
Omeros uses its proprietary high-throughput cellular redistribution assay (CRA) to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development. Omeros believes that it is the first to possess the capability to conduct high-throughput drug discovery for orphan GPCRs, and that currently there is no other existing high-throughput technology able to "unlock" orphan GPCRs. Unlocking these receptors could lead to the development of drugs that act at these new targets. There is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.Omeros has begun screening orphan GPCRs against its small-molecule chemical libraries using its proprietary, high-throughput CRA. In addition to Class A orphan GPCRs, we have also begun screening orphan and non-orphan Class B receptors. Class B GPCRs have large extracellular domains and their natural ligands are generally large peptides, making the development of orally active, small-molecule drugs against these receptors, such as glucagon and parathyroid hormone, a persistent challenge. Omeros has announced that it has identified and confirmed sets of compounds that interact selectively with the following orphan receptors: [See table at the top]In parallel, Omeros is executing on its intellectual property strategy to protect each unlocked target through a multipronged approach directed to compound structures, uniquely identified signaling pathways and associated therapeutic indications. Collectively, this approach provides Omeros the opportunity to establish broad and enforceable protection for each unlocked receptor.GPR17 We are optimizing compounds against GPR17, a G protein-coupled receptor (GPCR) which is linked to myelin formation. Myelin is an insulating layer rich in lipids and proteins that forms a sheath around the nerve fibers, which is essential for the proper functioning of the nervous system. Loss of the myelin sheath is the hallmark of several diseases, including multiple sclerosis, acute disseminated encephalomyelitis, Neuromyelitis Optica, transverse myelitis, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, central pontine myelinosis, inherited demyelinating diseases such as leukodystrophy, and Charcot-Marie-Tooth disease. We believe GPR17 inhibitors have the potential to promote remyelination and improve the outcome of these diseases as well as traumatic brain injury and spinal cord injury, conditions that have been associated with GPR17. Discovering GPR17 inhibitors has previously been challenging to the pharmaceutical industry because this receptor is an orphan GPCR, i.e., its natural ligand is not known, as discussed below. However, using our proprietary CRA, which allows compound screening against orphan GPCRs without knowledge of a given receptor's natural ligand, we have been able to identify over 120 compounds that functionally interact with GPR17. Patent Position As of February 28, 2015, we owned five issued patents and 16 pending patent applications in the U.S., and 43 issued patents and eight pending patent applications in foreign markets, which are directed to previously unknown links between specific molecular targets in the brain and a series of CNS disorders, our cellular redistribution assay and other research tools that are used in our GPCR program and to orphan GPCRs and other GPCRs for which we have identified functionally interacting compounds using our CRA. |
|
|
|
Post by sluggobear on Feb 4, 2016 17:02:34 GMT -5
I see no reason why a public company would want to spin off their drugs (in secret) so they could work with MNKD (not in secret). This makes no sense to me. I made these points below in another thread. Again, the possible answer I come up with is from these 3 bits of information: 1. looking at Mannkind's FAQ which states: How will Technosphere technology be used by the licensee? "Technosphere technology is to be used as a vehicle to deliver regulated doses of a proprietary compound to treat a variety of medical conditions, including chronic pain, spasticity and inflammatory diseases such as rheumatoid
arthritis." 2. We know it's Seattle-based investors. 3. We know they want to keep their identity and "proprietary compound" secret. Why? I contend that there is a HIGH likelihood that Receptor plans to deliver a proprietary compound of THC and/or CBD (cannabidiol) in controlled, regulated doses without smoke and without great variability. Pot is legal in WA. The secrecy around this makes me suspicious and this would provide a pretty good explanation. The medical conditions listed above have ALL been considered "treatable" by proponents of medical marijuana and many studies have been done to test for the efficacy of THC and CBD (and smoked pot) in these conditions and diseases. In fact, the American Academy of Neurology has reviewed the evidence for treatment of spasticity, MS and other neuro diseases using cannabis extracts. Here is a summary of their systematic review at the AAN website: www.aan.com/Guidelines/home/GetGuidelineContent/650Summary of Systematic Review for PATIENTS and their FAMILIES. MEDICAL MARIJUANA IN CERTAIN NEUROLOGICAL DISORDERS This is what I believe Receptor is doing. I would love to have THAT specific idea dispelled because I am very conflicted about the reality of medical marijuana. And just recently there was news that a CBD-like derivative drug cause stroke and death in a phase 1 study in France. Here's some of the info (I edited) from a Forbes article: "A Phase 1 drug trial in France left one dead and five others hospitalized (four with neurological damage) at the University of Rennes Central Hospital. The drug in question, BIA 10-2474, made by Portugal-based pharmaceutical company Bial-Portela & Ca., S.A., is being developed for pain relief, an area where non-addictive drugs are needed. BIA 10-2474 is an inhibitor of fatty acid amide hydrolase - FAAH. What’s so important about FAAH? Our bodies make several fatty acid amides that include anandamide, a natural stimulator of the cannabinoid receptors. Anandamide is referred to as an endocannabinoid. The rationale is that a drug blocking FAAH will allow naturally-occurring anandamide to accumulate and act on cannabinoid receptors in a manner that won’t produce the psychoactive effects of cannabis." Well let's go ahead and block all of those receptors...and then see what happens? Anyway that's another discussion. I think RLS may be developing inhaled THC and CBD. |
|
|
|
Post by raydonovan on Feb 4, 2016 17:06:41 GMT -5
Hello all, It seems like a lot of speculation here, but it seems that the Receptor Chief Scientific Officer is an ex MNKD employee, having worked there for 12 years; Andrea Leone-Bay Chief Scientific Officer at Receptor Life Sciences Greater New York City Area Pharmaceuticals Previous MannKind Corporations 213 connectionsSend Andrea InMailMore options Background Experience Chief Scientific Officer Receptor Life Sciences October 2015 – Present (5 months) Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. Vice President Pharmaceutical R&D MannKind Corporations 2003 – 2015 (12 years) |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 4, 2016 17:34:01 GMT -5
I see no reason why a public company would want to spin off their drugs (in secret) so they could work with MNKD (not in secret). This makes no sense to me. I made these points below in another thread. Again, the possible answer I come up with is from these 3 bits of information: 1. looking at Mannkind's FAQ which states: How will Technosphere technology be used by the licensee? "Technosphere technology is to be used as a vehicle to deliver regulated doses of a proprietary compound to treat a variety of medical conditions, including chronic pain, spasticity and inflammatory diseases such as rheumatoid
arthritis." 2. We know it's Seattle-based investors. 3. We know they want to keep their identity and "proprietary compound" secret. Why? I contend that there is a HIGH likelihood that Receptor plans to deliver a proprietary compound of THC and/or CBD (cannabidiol) in controlled, regulated doses without smoke and without great variability. Pot is legal in WA. The secrecy around this makes me suspicious and this would provide a pretty good explanation. The medical conditions listed above have ALL been considered "treatable" by proponents of medical marijuana and many studies have been done to test for the efficacy of THC and CBD (and smoked pot) in these conditions and diseases. In fact, the American Academy of Neurology has reviewed the evidence for treatment of spasticity, MS and other neuro diseases using cannabis extracts. Here is a summary of their systematic review at the AAN website: www.aan.com/Guidelines/home/GetGuidelineContent/650Summary of Systematic Review for PATIENTS and their FAMILIES. MEDICAL MARIJUANA IN CERTAIN NEUROLOGICAL DISORDERS This is what I believe Receptor is doing. I would love to have THAT specific idea dispelled because I am very conflicted about the reality of medical marijuana. And just recently there was news that a CBD-like derivative drug cause stroke and death in a phase 1 study in France. Here's some of the info (I edited) from a Forbes article: "A Phase 1 drug trial in France left one dead and five others hospitalized (four with neurological damage) at the University of Rennes Central Hospital. The drug in question, BIA 10-2474, made by Portugal-based pharmaceutical company Bial-Portela & Ca., S.A., is being developed for pain relief, an area where non-addictive drugs are needed. BIA 10-2474 is an inhibitor of fatty acid amide hydrolase - FAAH. What’s so important about FAAH? Our bodies make several fatty acid amides that include anandamide, a natural stimulator of the cannabinoid receptors. Anandamide is referred to as an endocannabinoid. The rationale is that a drug blocking FAAH will allow naturally-occurring anandamide to accumulate and act on cannabinoid receptors in a manner that won’t produce the psychoactive effects of cannabis." Well let's go ahead and block all of those receptors...and then see what happens? Anyway that's another discussion. I think RLS may be developing inhaled THC and CBD. and what would be the market size for such? and regulatory process? |
|
|
|
Post by sluggobear on Feb 4, 2016 20:58:06 GMT -5
Excellent questions!! I was hoping to at least have this discussion because IF TRUE (and I have no knowledge at all), this could be a game changer for MNKD this year. If RLS is planning to create a controlled dose, medical grade, inhalable THC and/or CBD product, once this approach becomes common knowledge, the street will understand the economics immediately. I hate to spread rumors and I really don't want to be "that guy". "Keep your pants on buddy!"  I may be totally wrong. "Medical marijuana" products are not regulated drugs at the moment. The purveyors of THC and CBD and "da kine" (from when I was a surfer dude in NoCal) make NO medical claims for their drugs. That's a big decision if RLS is in this business and decides not to make claims / take a regulatory path! I have gone through the FAQ's again to see if they say there is a "clinical program" and I do NOT see that. They do refer to the proprietary compound as a "pharmaceutical" but that does not mean it is a regulated product. If they are making an inhalable version of a now legal drug that already sells billions in the US, with the growth rate conservatively in the 30%+ range, and they can get this to the market very quickly (this year) - Mannkind may really rake in royalties as is also suggested in the FAQ's. "Researchers from The ArcView Group, a cannabis industry investment and research firm based in Oakland, California, found that the U.S. market for legal cannabis grew 74 percent in 2014 to $2.7 billion, up from $1.5 billion in 2013." From FAQ's: As they (RLS) proceed down the development path and achieve specific developmental goals, we receive milestone payments in recognition of the increasing value of our technology in their hands. Again, as is typical, the specific milestones and associated payments are not disclosed for competitive reasons, but I can say the first material milestone is expected to be received this year, if all goes according to plan. Total milestones that might be earned total over $100 million, but the real value of this license would come from royalties if successful. - See more at: investors.mannkindcorp.com/faq.cfm?faqid=2#sthash.rpVjFSny.dpufTechnosphere’s value proposition is the immediate delivery of a consistent and precise dosage of the prescribed amount of an active therapeutic compound, while reducing unwanted side effects. In addition, MannKind’s inhalers are convenient, discreet and easy-to-use from patients’ perspective as well as being a robust and low-cost delivery system from a manufacturing perspective. - See more at: investors.mannkindcorp.com/faq.cfm?faqid=2#sthash.rpVjFSny.dpuf |
|
|
|
Post by figglebird on Feb 4, 2016 21:12:39 GMT -5
Okay - first interesting post of the day - cannot conceive how THC could be propriatary - could be an acconpanied compound that is inactive but bit of a fetch.
Good thinking though.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 4, 2016 21:16:59 GMT -5
Excellent questions!! I was hoping to at least have this discussion because IF TRUE (and I have no knowledge at all), this could be a game changer for MNKD this year. If RLS is planning to create a controlled dose, medical grade, inhalable THC and/or CBD product, once this approach becomes common knowledge, the street will understand the economics immediately. I hate to spread rumors and I really don't want to be "that guy". "Keep your pants on buddy!" I may be totally wrong. "Medical marijuana" products are not regulated drugs at the moment. The purveyors of THC and CBD and "da kine" (from when I was a surfer dude in NoCal) make NO medical claims for their drugs. That's a big decision if RLS is in this business and decides not to make claims / take a regulatory path! I have gone through the FAQ's again to see if they say there is a "clinical program" and I do NOT see that. They do refer to the proprietary compound as a "pharmaceutical" but that does not mean it is a regulated product. If they are making an inhalable version of a now legal drug that already sells billions in the US, with the growth rate conservatively in the 30%+ range, and they can get this to the market very quickly (this year) - Mannkind may really rake in royalties as is also suggested in the FAQ's. "Researchers from The ArcView Group, a cannabis industry investment and research firm based in Oakland, California, found that the U.S. market for legal cannabis grew 74 percent in 2014 to $2.7 billion, up from $1.5 billion in 2013." From FAQ's: As they (RLS) proceed down the development path and achieve specific developmental goals, we receive milestone payments in recognition of the increasing value of our technology in their hands. Again, as is typical, the specific milestones and associated payments are not disclosed for competitive reasons, but I can say the first material milestone is expected to be received this year, if all goes according to plan. Total milestones that might be earned total over $100 million, but the real value of this license would come from royalties if successful. - See more at: investors.mannkindcorp.com/faq.cfm?faqid=2#sthash.rpVjFSny.dpufTechnosphere’s value proposition is the immediate delivery of a consistent and precise dosage of the prescribed amount of an active therapeutic compound, while reducing unwanted side effects. In addition, MannKind’s inhalers are convenient, discreet and easy-to-use from patients’ perspective as well as being a robust and low-cost delivery system from a manufacturing perspective. - See more at: investors.mannkindcorp.com/faq.cfm?faqid=2#sthash.rpVjFSny.dpuf
This is because marijuana is absorbed much slower by the stomach than the lungs, which causes the effect to be delayed by up to an hour. Absorption by the stomach also tends to be uneven, since cannabinoids are first metabolized by the liver before entering the blood stream.
On the other hand, the lungs absorb cannabinoids in a matter of seconds, providing almost instant relief when cannabis vapor is inhaled. Vaporizers also give patients better control over dosing, since it is easy to stop inhaling once the desired effect is achieved.
For these reasons, doctors often recommend using a vaporizer over oral preparations of cannabis. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 4, 2016 21:20:50 GMT -5
Okay - first interesting post of the day - cannot conceive how THC could be propriatary - could be an acconpanied compound that is inactive but bit of a fetch. Good thinking though. proprietary as in "Its not mannkind's , its RLS's" |
|
|
|
Post by patten1962 on Feb 4, 2016 21:47:51 GMT -5
This company does seem to fit the profile of some the indicators mentioned in the press release.
ABOUT OMEROS
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
PIPELINE
Omeros is developing a deep pipeline of small-molecule and protein therapeutic candidates targeting inflammation, coagulopathies, and disorders of the central nervous system. Our twelve programs include those focused on inflammation, coagulopathies, and multiple CNS disorders, as well as our three platform programs: PharmacoSurgery®, antibody and G protein-coupled receptor all targeting both large-market and exciting orphan opportunities.
Source: www.omeros.com/pipeline/pipeline.htm
NOTE: Omeros is a public-traded company, however [NASDAQ: OMER]. Unless they are planning a spinoff, there is no indication of an imminent name-change.
This company had a 4pm cc. Did they say anything? |
|
|
|
Post by figglebird on Feb 4, 2016 21:55:45 GMT -5
What? THC could belong as much to mannkind as anyone. Proprietary = exclusive?
Unless I woke up in a different universe.
|
|
|
|
Post by kc on Feb 4, 2016 22:47:49 GMT -5
Okay - first interesting post of the day - cannot conceive how THC could be propriatary - could be an acconpanied compound that is inactive but bit of a fetch. Good thinking though. perhaps in the way the dosage is regulated and consistency with Technosphere. The problem with Medical MJ is that there is no batch to batch consistency that I know of and that is what makes it currently dangerous. Perhaps the way that its freeze dried and put into the Technosphere will make it uniformly consistent. |
|
|
|
Post by figglebird on Feb 4, 2016 23:04:44 GMT -5
Umm... Okay... I use a lot of medical marijuana in the form of edibles - wait now that I think about it... hmmm... I don't know.
|
|
|
|
Post by 4allthemarbles on Feb 5, 2016 1:50:49 GMT -5
Ok kids- the last 2 pages (of this 9 page thread) are sounding fun. So here's the deal: Google- of course that would be awesome, just hard to swallow without Kool-aid, but it would be my fav.
Omeros- much more normal thinking that could make sense. Boring sense in comparison to GOOGLE!
The third thing- THC- Now we're talking. Batch consistency could be made- think about edibles - the product- the THC is cooked out of the plant to make butter or oil.
Still with me here? Good! That's how they control how much THC gets loaded onto techno sphere particles. So, you would always get the same medicine each time. Those compound go to our compounds and then we become righ, stoned, happy and retired.
This is freaking genius!
But I have also been drinking. Does someone with a clear mind understand where I am going with this.
|
|
I may be totally wrong.
